BCL2 and B-cell chronic lymphocytic leukemia: Despite impressive progress with the recent approval of BTK and/or BCL2 inhibitors, the treatment of R/R CLL may represent an unmet need for patients carrying coexisting medical conditions which complicate these treatment options.